BRIEF — Biocad invests $26 million into infrastructure for creating gene therapies

Russian biotech Biocad is to invest around $26 million into infrastructure for creating gene therapies.

This is part of an agreement focusing on research into CAR-T therapies between Biocad and the National Medical Research Center, Almazov.

The Deputy Minister of Health of the Russian Federation, Sergey Kraevoy, was also at the signing to reflect state support for the research.